pdf   xlsx method abbreviations

mNSCLC - L1 - PDL1 positive, pembrolizumab plus ipilimumab , meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths (OS) 1.08 [0.85, 1.37]< 10%1 study (1/-)26.4 %NAnot evaluable crucial-
progression or deaths (PFS) 1.06 [0.86, 1.30]< 10%1 study (1/-)29.0 %NAnot evaluable important-
objective responses (ORR) 1.00 [0.72, 1.39]> 10%1 study (1/-)50.0 %NAnot evaluable non important-

AE (grade 3-4) endpoints 00

Anaemia AE (grade 3-4) 1.14 [0.41, 3.20]< 10%1 study (1/-)40.0 %NAnot evaluable non important-
Arthralgia AE (grade 3-4) 2.01 [0.36, 11.05]< 10%1 study (1/-)21.3 %NAnot evaluable non important-
Asthenia AE (grade 3-4) 0.25 [0.03, 2.22]< 10%1 study (1/-)89.3 %NAnot evaluable non important-
Back pain AE (grade 3-4) 0.50 [0.04, 5.51]< 10%1 study (1/-)71.4 %NAnot evaluable non important-
Constipation AE (grade 3-4) 1.00 [0.14, 7.12]< 10%1 study (1/-)50.1 %NAnot evaluable non important-
Cough AE (grade 3-4) 0.50 [0.02, 14.89]< 10%1 study (1/-)65.4 %NAnot evaluable non important-
Decreased appetite AE (grade 3-4) 6.03 [0.30, 120.98]< 10%1 study (1/-)12.3 %NAnot evaluable non important-
Diarrhoea AE (grade 3-4) 10.29 [1.31, 80.96]< 10%1 study (1/-)1.4 %NAnot evaluable non important-
Dyspnoea AE (grade 3-4) 0.87 [0.31, 2.43]< 10%1 study (1/-)60.6 %NAnot evaluable non important-
Fatigue AE (grade 3-4) 1.51 [0.42, 5.39]< 10%1 study (1/-)26.5 %NAnot evaluable non important-
Hypothyroidism AE (grade 3-4) 1.00 [0.06, 16.01]< 10%1 study (1/-)50.1 %NAnot evaluable non important-
Increase AST AE (grade 3-4) 2.52 [0.48, 13.09]< 10%1 study (1/-)13.7 %NAnot evaluable non important-
Increased ALT AE (grade 3-4) 2.28 [0.69, 7.50]< 10%1 study (1/-)8.7 %NAnot evaluable non important-
Nausea AE (grade 3-4) 4.01 [0.18, 89.26]< 10%1 study (1/-)19.3 %NAnot evaluable non important-
Pneumonia AE (grade 3-4) 1.36 [0.72, 2.56]< 10%1 study (1/-)17.2 %NAnot evaluable non important-
Pneumonitis AE (grade 3-4) 2.21 [0.83, 5.91]< 10%1 study (1/-)5.6 %NAnot evaluable non important-
Pruritus AE (grade 3-4) 0.50 [0.04, 5.51]< 10%1 study (1/-)71.4 %NAnot evaluable non important-
Pyrexia AE (grade 3-4) 6.03 [0.30, 120.98]< 10%1 study (1/-)12.3 %NAnot evaluable non important-
Rash AE (grade 3-4) 16.38 [0.94, 286.59]< 10%1 study (1/-)2.9 %NAnot evaluable non important-
Vomiting AE (grade 3-4) 4.03 [0.45, 36.27]< 10%1 study (1/-)10.8 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons